Urteste S.A. has launched a European multicenter clinical study of the Panuri test, an IVD medical device for detecting pancreatic cancer. The study, conducted in multiple centers in Poland, Hungary, and Italy, is a key milestone in the commercialization strategy for Urteste’s solution. The study aims to characterize the effectiveness of the Panuri test in detecting pancreatic cancer, with sensitivity and specificity as primary endpoints. The study will involve 550 participants and is expected to provide valuable clinical data for the certification process of the medical device in Europe, with potential implications for a planned study in the US.

Read more at GlobeNewswire: Urteste S.A. launches European multicenter clinical study